$7.64
+0.00%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$7.52
From 52W high−21.40%
Volume518965.00
Market cap$5.20B
P/E (TTM)10.2x
P/S (TTM)0.6x
Div yield1.24%
Key dataOct 19, 2026
Open
$7.52
From 52W high
−21.40%
Volume
518965.00
Market cap
$5.20B
ValuationView details →
P/E (Fwd)
19.7x
EV/EBITDA
8.6x
P/E (TTM)
10.2x
RSI (14)
56.9
MomentumView details →
1D Return
+0.00%
YTD Return
−18.34%
SummaryUpdated Jun 1, 2026
Grifols, S.A. (NASDAQ:GRFS) is a Spanish multinational pharmaceutical and chemical company founded in 1940 and headquartered in Barcelona, Spain. The company went public on NASDAQ in 2011 and has grown to become one of the world's largest producers of plasma-derived medicines. Grifols operates through multiple divisions including Bioscience, Hospital, Diagnostic, and Bio Supplies, serving healthcare providers globally with products used to treat chronic, rare, and life-threatening diseases. The company has undergone significant operational restructuring in recent years, including leadership changes with Nacho Abia becoming CEO in 2024, as it works to improve financial performance and reduce leverage following a period of rapid expansion.
Similar companies
Latest newsMore news →
Grifols SA and allied health coalitions called on the federal government to close Grifols’ paid-plasma centres, terminate the contract between Canadian Blood Services and Grifols, and launch an independent federal inquiry into deaths connected to Grifols locations in Winnipeg.3d agoThe Grifols SA donated $25,000 to Feed the Boro to support about 10 months of food for its monthly food drops.11d agoHealth Canada suspended Grifols's licence for its Taylor Avenue plasma collection centre in Winnipeg effective immediately, citing an ineffective quality management system.26d ago